NextenBio Participates in Investment in Cloud Native AI Specialist Company Clush

NextenBio's invested cloud-native specialist company, Clush, aims to provide turnkey services encompassing AI and data by overseeing applications developed, deployed, and operated in cloud environments, unlike traditional IT infrastructure.

Recently, Clush (formerly KBSYS) announced its entry into the cloud-native market in earnest by changing its name and acquiring FDX, a specialist in AI data and security.

The core of cloud-native technology lies in microservices architecture, containerization, automation, and scaling. By dividing applications into small, independent services, it enhances flexibility and scalability while running in virtualized environments to simplify development and deployment and maintain consistency. Systems built in cloud-native environments automate operational processes to improve productivity, minimize errors, and respond to traffic increases by automatically allocating resources through scaling. These advantages have accelerated adoption across various industries.

An Aon Investment official who led this investment stated, “Innogrid, a cloud specialist currently undergoing IPO this year, has already been valued at over 100 billion KRW, and Orchestr, another cloud specialist that attracted investments exceeding 130 billion KRW from IMM Investment and others, was recognized with a corporate value of about 630 billion KRW in 2023. Clush is also expected to stand shoulder to shoulder with these companies in the near future.”

A NextenBio representative said, “Cloud-native technology is being strategically applied not only from a technical perspective but across the entire bio industry, playing a crucial role in securing future competitiveness,” adding, “It will lead to the emergence of AI-based healthcare platforms trained using cloud-native systems and collected bio big data on top of existing cloud infrastructure.”

They continued, “We expect it to serve as a technological catalyst that can maximize the added value by integrating medical data into cloud environments, and we plan to actively collaborate with Clush moving forward.”

Meanwhile, Robis Biotherapeutics, in which NextenBio made an early investment and is developing a miRNA-based new drug for diabetes treatment, has established RX-BIO to develop veterinary pharmaceuticals and is preparing to enter the companion animal market.